 <h1>Cycloset Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>bromocriptine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about bromocriptine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Cycloset.</p><h2>In Summary</h2><p><b>Common side effects of Cycloset include:</b> symptomatic hypotension.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to bromocriptine: oral capsule, oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, bromocriptine (the active ingredient contained in Cycloset) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking bromocriptine:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>chest pain or discomfort</li>
<li>difficulty in speaking</li>
<li>dizziness or lightheadedness, especially when getting up suddenly from a lying or sitting position</li>
<li>double vision</li>
<li>feeling, seeing, or hearing things that are not there</li>
<li>feeling that others are watching you or controlling your behavior</li>
<li>feeling that others can hear your thoughts</li>
<li>headache</li>
<li>inability to move the arms, legs, or facial muscles</li>
<li>inability to speak</li>
<li>nausea</li>
<li>nervousness</li>
<li>pain or discomfort in the arms, jaw, back, or neck</li>
<li>pounding in the ears</li>
<li>severe mood or mental changes</li>
<li>slow or fast heartbeat</li>
<li>slow speech</li>
<li>sweating</li>
<li>trouble breathing</li>
<li>unusual behavior</li>
<li>vomiting</li>
</ul><p>
<i>Less common—reported more often in patients with Parkinson's disease </i>
</p><ul>
<li>Confusion</li>
<li>uncontrolled movements of the body, such as the face, tongue, arms, hands, head, and upper body</li>
</ul><p>
<i>Rare—reported more often in patients taking large doses</i>
</p><ul>
<li>Increased frequency of urination</li>
<li>loss of appetite, continuing</li>
<li>lower back pain</li>
<li>runny nose, continuing</li>
<li>stomach pain, continuing or severe</li>
<li>weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bloody vomit</li>
<li>fainting</li>
<li>nausea</li>
<li>nervousness</li>
<li>seizures</li>
<li>sudden weakness</li>
<li>temporary blindness</li>
<li>unusual headache</li>
<li>vomiting, continuing or severe</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>anxiety</li>
<li>blue or pale skin</li>
<li>chest pain, possibly moving to the left arm, neck, or shoulder</li>
<li>chills</li>
<li>difficulty in speaking</li>
<li>double vision</li>
<li>false beliefs that cannot be changed by facts</li>
<li>fever</li>
<li>headache</li>
<li>high fever</li>
<li>high or low blood pressure</li>
<li>inability to move the arms, legs, or facial muscles</li>
<li>inability to speak</li>
<li>increased frequency of urination</li>
<li>loss of bladder control</li>
<li>lower back pain</li>
<li>severe muscle stiffness</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
<li>unusually pale skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of bromocriptine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Constipation</li>
<li>diarrhea</li>
<li>drowsiness or tiredness</li>
<li>dry mouth</li>
<li>leg cramps at night</li>
<li>loss of appetite</li>
<li>mental depression</li>
<li>stomach pain</li>
<li>stuffy nose</li>
<li>tingling or pain in the fingers and toes when exposed to cold temperatures</li>
</ul><p>
<!-- end oral capsule, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bromocriptine: compounding powder, oral capsule, oral tablet</i></p><h3>General</h3><p>The incidence of adverse reactions with this drug are high, but generally mild to moderate in degree.  The most commonly reported adverse reactions have included nausea, headache, dizziness, vomiting, and fatigue.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Retroperitoneal fibrosis has been reported in a few patients receiving this drug in doses ranging from 30 to 140 mg/day for 2 to 10 years.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Nausea (up to 49%), constipation (12.5%) </p>
<p><b>Common</b> (1% to 10%): Dyspepsia, vomiting, abdominal cramps, diarrhea</p>
<p><b>Frequency not reported</b>: Severe gastrointestinal bleeding from peptic ulcers (including fatalities), dry mouth</p>
<p><b>Postmarketing reports</b>: Retroperitoneal fibrosis, gastrointestinal ulcer<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Symptomatic hypotension has been reported in patients receiving this drug for any indication.  Syncope and symptomatic hypotension (decreases in supine systolic and diastolic pressures of greater than 20 mm and 10 mm Hg, respectively) have been reported in approximately 30% of postpartum patients.  Rare cases of serious adverse events including hypertension, myocardial infarction, seizures, and strokes, have been reported in postpartum women.  Patients experiencing seizures and/or strokes have reported developing a continuous headache, often progressively severe, hours to days prior to the acute event.  In addition, visual disturbances (blurred vision and transient cortical blindness) have been reported to also precede stroke and/or seizure events.  </p>
<p></p>
<p>Type 2 diabetes mellitus trials: Syncope was reported in 1.5% of patients; the cause of syncope was not known in all cases.  In a 52-week safety trial in which all serious adverse events and cardiovascular endpoints were adjudicated, serious adverse events occurred in 8.5% of drug treated patients compared with 9.6% of placebo patients.  The composite cardiovascular endpoint occurred in 31 (1.5%) drug-treated patients and 30 (3%) placebo patients.  </p>
<p></p>
<p>Fibrotic complications including cases of retroperitoneal fibrosis, pulmonary fibrosis, pleural effusion, pleural thickening, pericarditis, and pericardial effusions have been reported during postmarketing period.  These reports have been more commonly received in patients on long-term and high-dose treatment.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Syncope, hypotension, orthostatic hypotension, cold-sensitive digital vasospasm</p>
<p><b>Rare</b> (0.01% to 0.1%): Hypertension</p>
<p><b>Frequency not reported</b>: Myocardial infarction, arrhythmia, ventricular tachycardia, bradycardia, ankle and feet edema, signs and symptoms of ergotism (e.g., tingling of fingers, cold feet, numbness, muscle cramps of feet and legs or exacerbation of Raynaud's syndrome) </p>
<p><b>Postmarketing reports</b>: Cardiac valvulopathy, pericarditis, pericardial effusions, constrictive pericarditis, cardiac valve fibrosis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>This drug, alone or in combination with levodopa, may cause hallucinations (visual or auditory).  Hallucinations usually resolve with dosage reduction; occasionally, discontinuation of the drug is required.  Rarely, after high doses, hallucinations have persisted for several weeks after discontinuation of the drug.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Insomnia, paranoia, depression, anxiety, nervousness, nightmares, "on-off" phenomenon</p>
<p><b>Postmarketing reports</b>: Hallucinations, mental confusion, psychomotor agitation/excitation, increased libido, hypersexuality, pathological gambling, increased sexual urges, intense urges to spend money uncontrollably, other intense urges<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 19%), Dizziness (up to 17%) </p>
<p><b>Common</b> (1% to 10%): Somnolence, lightheadedness, dyskinesia, ataxia</p>
<p><b>Frequency not reported</b>: Cerebrospinal fluid rhinorrhea, paresthesia, vasovagal attack, seizures</p>
<p><b>Postmarketing reports</b>: Stroke, neuroleptic-like malignant syndrome upon cessation in patients with Parkinson's disease, sudden sleep onset<sup>[Ref]</sup></p><p>A few cases of cerebrospinal fluid rhinorrhea have been reported in patients with large prolactinomas who have received previous transsphenoidal surgery, pituitary radiation, or both.  It may also occur in previously untreated patients whose tumor extends into the sphenoid sinus.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Fibrotic complications including cases of retroperitoneal fibrosis, pulmonary fibrosis, pleural effusion, pleural thickening, pericarditis, and pericardial effusions have been reported during postmarketing approval use of this drug.  These reports have been more commonly received in patients on long-term and high-dose treatment.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Rhinitis (up to 13.8%), sinusitis (10%) </p>
<p><b>Common</b> (1% to 10%): Nasal congestion</p>
<p><b>Frequency not reported</b>: Shortness of breath, nasal stuffiness </p>
<p><b>Postmarketing reports</b>: Pulmonary fibrosis, pleural effusion, pleural thickening, pleural fibrosis, pleurisy, dyspnea<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Amblyopia</p>
<p><b>Frequency not reported</b>: Blepharospasm</p>
<p><b>Postmarketing reports</b>: Visual disturbance, vision blurred<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Muscle cramps</p>
<p><b>Postmarketing reports</b>: Leg cramps<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary frequency, urinary incontinence, urinary retention<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Hair loss, erythromelalgia, mottling of skin, skin rash</p>
<p><b>Postmarketing reports</b>: Allergic skin reactions<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (up to 18.9%), fatigue (up to 13.9%)</p>
<p><b>Frequency not reported</b>: Vertigo, sluggishness, lassitude, alcohol potentiation</p>
<p><b>Postmarketing reports</b>: Tinnitus<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Allergic skin reactions</p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Growth hormone-secreting tumor expansion in patients with acromegaly</p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Infection, flu syndrome</p><h3>Metabolic</h3><p>In the monotherapy trial in patients with type 2 diabetes mellitus, hypoglycemia was reported in 2 patients (3.7%).  In the add-on to sulfonylurea trials, hypoglycemia was reported in 8.6% of patients.</p><p><b>Common</b> (1% to 10%): Anorexia, hypoglycemia</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Cycloset (bromocriptine)." Valeant Pharmaceuticals, Costa Mesa, CA. </p><p id="ref_2">2. "Product Information. Parlodel (bromocriptine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ. </p><p id="ref_3">3. Larrazet F, Spaulding C, Lobreau HJ, Weber S, Guerin F "Possible bromocriptine-induced myocardial infarction." Ann Intern Med 118 (1993): 199-200</p><p id="ref_4">4. Kaushik P,  Vatsavai SR,  Banda VR,  Sanghi PK,  Ahmad M,  Kaushik R "Acute onset of severe dilated cardiomyopathy during bromocriptine therapy." Ann Pharmacother 38 (2004): 1219-21</p><p id="ref_5">5. Champagne SP, Coste E, Peyriere H, Nigond J, Mania E, Pons M, HillaireBuys D, Balmes P, Blayac JP, Davy JM "Chronic constrictive pericarditis induced by long-term bromocriptine therapy: Report of two cases." Ann Pharmacother 33 (1999): 1050-4</p><p id="ref_6">6. Boyd A "Bromocriptine and psychosis: a literature review." Psychiatr Q 66 (1995): 87-95</p><p id="ref_7">7. Dorevitch A, Aronzon R, Stark M "Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia." Acta Obstet Gynecol Scand 70 (1991): 375-6</p><p id="ref_8">8. Peter SA, Autz A, Jean-Simon ML "Bromocriptine-induced schizophrenia." J Natl Med Assoc 85 (1993): 700-1</p><p id="ref_9">9. Bende M, Bergman B, Sjogren C "Nasal mucosal congestion after treatment with bromocriptine." Laryngoscope 103 (1993): 1142-4</p><p id="ref_10">10. Couldwell WT, Weiss MH "Visual loss associated with bromocriptine." Lancet 340 (1992): 1210-411</p><p id="ref_11">11. Leiguarda R, Merello M, Sabe L, Starkstein S "Bromocriptine-induced dystonia in patients with aphasia and hemiparesis." Neurology 43 (1993): 2319-22</p><p id="ref_12">12. Fabre N, Montastruc JL, Rascol O "Alopecia: an adverse effect of bromocriptine." Clin Neuropharmacol 16 (1993): 266-8</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Cycloset (bromocriptine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: dopaminergic antiparkinsonism agents</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cycloset &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Parlodel</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bromocriptine: compounding powder, oral capsule, oral tablet</i></p><h3>General</h3><p>The incidence of adverse reactions with this drug are high, but generally mild to moderate in degree.  The most commonly reported adverse reactions have included nausea, headache, dizziness, vomiting, and fatigue.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Retroperitoneal fibrosis has been reported in a few patients receiving this drug in doses ranging from 30 to 140 mg/day for 2 to 10 years.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Nausea (up to 49%), constipation (12.5%) </p><p><b>Common</b> (1% to 10%): Dyspepsia, vomiting, abdominal cramps, diarrhea</p><p><b>Frequency not reported</b>: Severe gastrointestinal bleeding from peptic ulcers (including fatalities), dry mouth</p><p><b>Postmarketing reports</b>: Retroperitoneal fibrosis, gastrointestinal ulcer<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Symptomatic hypotension has been reported in patients receiving this drug for any indication.  Syncope and symptomatic hypotension (decreases in supine systolic and diastolic pressures of greater than 20 mm and 10 mm Hg, respectively) have been reported in approximately 30% of postpartum patients.  Rare cases of serious adverse events including hypertension, myocardial infarction, seizures, and strokes, have been reported in postpartum women.  Patients experiencing seizures and/or strokes have reported developing a continuous headache, often progressively severe, hours to days prior to the acute event.  In addition, visual disturbances (blurred vision and transient cortical blindness) have been reported to also precede stroke and/or seizure events.  </p><p></p><p>Type 2 diabetes mellitus trials: Syncope was reported in 1.5% of patients; the cause of syncope was not known in all cases.  In a 52-week safety trial in which all serious adverse events and cardiovascular endpoints were adjudicated, serious adverse events occurred in 8.5% of drug treated patients compared with 9.6% of placebo patients.  The composite cardiovascular endpoint occurred in 31 (1.5%) drug-treated patients and 30 (3%) placebo patients.  </p><p></p><p>Fibrotic complications including cases of retroperitoneal fibrosis, pulmonary fibrosis, pleural effusion, pleural thickening, pericarditis, and pericardial effusions have been reported during postmarketing period.  These reports have been more commonly received in patients on long-term and high-dose treatment.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Syncope, hypotension, orthostatic hypotension, cold-sensitive digital vasospasm</p><p><b>Rare</b> (0.01% to 0.1%): Hypertension</p><p><b>Frequency not reported</b>: Myocardial infarction, arrhythmia, ventricular tachycardia, bradycardia, ankle and feet edema, signs and symptoms of ergotism (e.g., tingling of fingers, cold feet, numbness, muscle cramps of feet and legs or exacerbation of Raynaud's syndrome) </p><p><b>Postmarketing reports</b>: Cardiac valvulopathy, pericarditis, pericardial effusions, constrictive pericarditis, cardiac valve fibrosis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>This drug, alone or in combination with levodopa, may cause hallucinations (visual or auditory).  Hallucinations usually resolve with dosage reduction; occasionally, discontinuation of the drug is required.  Rarely, after high doses, hallucinations have persisted for several weeks after discontinuation of the drug.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Insomnia, paranoia, depression, anxiety, nervousness, nightmares, "on-off" phenomenon</p><p><b>Postmarketing reports</b>: Hallucinations, mental confusion, psychomotor agitation/excitation, increased libido, hypersexuality, pathological gambling, increased sexual urges, intense urges to spend money uncontrollably, other intense urges<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 19%), Dizziness (up to 17%) </p><p><b>Common</b> (1% to 10%): Somnolence, lightheadedness, dyskinesia, ataxia</p><p><b>Frequency not reported</b>: Cerebrospinal fluid rhinorrhea, paresthesia, vasovagal attack, seizures</p><p><b>Postmarketing reports</b>: Stroke, neuroleptic-like malignant syndrome upon cessation in patients with Parkinson's disease, sudden sleep onset<sup>[Ref]</sup></p><p>A few cases of cerebrospinal fluid rhinorrhea have been reported in patients with large prolactinomas who have received previous transsphenoidal surgery, pituitary radiation, or both.  It may also occur in previously untreated patients whose tumor extends into the sphenoid sinus.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Fibrotic complications including cases of retroperitoneal fibrosis, pulmonary fibrosis, pleural effusion, pleural thickening, pericarditis, and pericardial effusions have been reported during postmarketing approval use of this drug.  These reports have been more commonly received in patients on long-term and high-dose treatment.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Rhinitis (up to 13.8%), sinusitis (10%) </p><p><b>Common</b> (1% to 10%): Nasal congestion</p><p><b>Frequency not reported</b>: Shortness of breath, nasal stuffiness </p><p><b>Postmarketing reports</b>: Pulmonary fibrosis, pleural effusion, pleural thickening, pleural fibrosis, pleurisy, dyspnea<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Amblyopia</p><p><b>Frequency not reported</b>: Blepharospasm</p><p><b>Postmarketing reports</b>: Visual disturbance, vision blurred<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Muscle cramps</p><p><b>Postmarketing reports</b>: Leg cramps<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary frequency, urinary incontinence, urinary retention<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Hair loss, erythromelalgia, mottling of skin, skin rash</p><p><b>Postmarketing reports</b>: Allergic skin reactions<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (up to 18.9%), fatigue (up to 13.9%)</p><p><b>Frequency not reported</b>: Vertigo, sluggishness, lassitude, alcohol potentiation</p><p><b>Postmarketing reports</b>: Tinnitus<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Allergic skin reactions</p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Growth hormone-secreting tumor expansion in patients with acromegaly</p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Infection, flu syndrome</p><h3>Metabolic</h3><p>In the monotherapy trial in patients with type 2 diabetes mellitus, hypoglycemia was reported in 2 patients (3.7%).  In the add-on to sulfonylurea trials, hypoglycemia was reported in 8.6% of patients.</p><p><b>Common</b> (1% to 10%): Anorexia, hypoglycemia</p><p id="ref_1">1. "Product Information. Cycloset (bromocriptine)." Valeant Pharmaceuticals, Costa Mesa, CA. </p><p id="ref_2">2. "Product Information. Parlodel (bromocriptine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ. </p><p id="ref_3">3. Larrazet F, Spaulding C, Lobreau HJ, Weber S, Guerin F "Possible bromocriptine-induced myocardial infarction." Ann Intern Med 118 (1993): 199-200</p><p id="ref_4">4. Kaushik P,  Vatsavai SR,  Banda VR,  Sanghi PK,  Ahmad M,  Kaushik R "Acute onset of severe dilated cardiomyopathy during bromocriptine therapy." Ann Pharmacother 38 (2004): 1219-21</p><p id="ref_5">5. Champagne SP, Coste E, Peyriere H, Nigond J, Mania E, Pons M, HillaireBuys D, Balmes P, Blayac JP, Davy JM "Chronic constrictive pericarditis induced by long-term bromocriptine therapy: Report of two cases." Ann Pharmacother 33 (1999): 1050-4</p><p id="ref_6">6. Boyd A "Bromocriptine and psychosis: a literature review." Psychiatr Q 66 (1995): 87-95</p><p id="ref_7">7. Dorevitch A, Aronzon R, Stark M "Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia." Acta Obstet Gynecol Scand 70 (1991): 375-6</p><p id="ref_8">8. Peter SA, Autz A, Jean-Simon ML "Bromocriptine-induced schizophrenia." J Natl Med Assoc 85 (1993): 700-1</p><p id="ref_9">9. Bende M, Bergman B, Sjogren C "Nasal mucosal congestion after treatment with bromocriptine." Laryngoscope 103 (1993): 1142-4</p><p id="ref_10">10. Couldwell WT, Weiss MH "Visual loss associated with bromocriptine." Lancet 340 (1992): 1210-411</p><p id="ref_11">11. Leiguarda R, Merello M, Sabe L, Starkstein S "Bromocriptine-induced dystonia in patients with aphasia and hemiparesis." Neurology 43 (1993): 2319-22</p><p id="ref_12">12. Fabre N, Montastruc JL, Rascol O "Alopecia: an adverse effect of bromocriptine." Clin Neuropharmacol 16 (1993): 266-8</p><h2>More about Cycloset (bromocriptine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: dopaminergic antiparkinsonism agents</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cycloset &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>